PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications.
+ 1 more risk
Excellent balance sheet with limited growth.
Share Price & News
How has PhaseBio Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2K4's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2K4 exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 2K4 exceeded the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is PhaseBio Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is PhaseBio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2K4's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2K4's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2K4 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2K4 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2K4's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2K4 is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).
How is PhaseBio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2K4 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2K4 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2K4 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2K4's revenue (78.2% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: 2K4's revenue (78.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2K4's Return on Equity is forecast to be high in 3 years time
How has PhaseBio Pharmaceuticals performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2K4 is currently unprofitable.
Growing Profit Margin: 2K4 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2K4's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2K4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2K4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 2K4 has a negative Return on Equity (-46.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is PhaseBio Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 2K4's short term assets ($83.4M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: 2K4's short term assets ($83.4M) exceed its long term liabilities ($9.4M).
Debt to Equity History and Analysis
Debt Level: 2K4's debt to equity ratio (13.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2K4's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 2K4 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 2K4's debt is covered by short term assets (assets are 8.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2K4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2K4 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -55.4% each year.
What is PhaseBio Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 2K4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2K4's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2K4's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2K4's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2K4's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jonathan Mow (54yo)
Mr. Jonathan P. Mow, MBA has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. since March 2015 and serves as its President. Mr. Mow served as Chief Business Officer of PhaseBio Pharmaceutical ...
CEO Compensation Analysis
Compensation vs Market: Jonathan's total compensation ($USD595.63K) is above average for companies of similar size in the German market ($USD412.37K).
Compensation vs Earnings: Jonathan's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||3.8yrs||US$465.43k||0.12% $153.8k|
|Chief Medical Officer||3.8yrs||US$501.05k||no data|
|VP & Head of Legal||0.3yrs||no data||no data|
|Vice President of Corporate Development & Commercial Strategy||1.7yrs||no data||0.0052% $6.6k|
|Vice President of Human Resources||0.3yrs||no data||no data|
Experienced Management: 2K4's management team is considered experienced (2.8 years average tenure).
|Independent Director||1yrs||no data||no data|
|Independent Director||1.2yrs||US$171.97k||no data|
|Chairman of the Board||0yrs||US$17.23k||0.055% $69.4k|
|Independent Director||1.6yrs||US$124.59k||no data|
|Independent Director||1.9yrs||US$80.60k||0.0035% $4.4k|
|Independent Director||10.1yrs||US$9.12k||0.0080% $10.1k|
|Director||0yrs||no data||no data|
Experienced Board: 2K4's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 3248.2%.
PhaseBio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PhaseBio Pharmaceuticals, Inc.
- Ticker: 2K4
- Exchange: DB
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$136.928m
- Listing Market Cap: US$126.384m
- Shares outstanding: 28.77m
- Website: https://www.phasebio.com
Number of Employees
- PhaseBio Pharmaceuticals, Inc.
- 1 Great Valley Parkway
- Suite 30
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHAS||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Oct 2018|
|2K4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2018|
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:59|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.